Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3492511rdf:typepubmed:Citationlld:pubmed
pubmed-article:3492511lifeskim:mentionsumls-concept:C0026769lld:lifeskim
pubmed-article:3492511lifeskim:mentionsumls-concept:C1155065lld:lifeskim
pubmed-article:3492511lifeskim:mentionsumls-concept:C1332714lld:lifeskim
pubmed-article:3492511pubmed:issue1lld:pubmed
pubmed-article:3492511pubmed:dateCreated1987-3-6lld:pubmed
pubmed-article:3492511pubmed:abstractTextInterleukin-2 (IL-2) production by CD4-enriched T cells from multiple sclerosis (MS) patients and normal individuals stimulated with concanavalin A (conA) and/or autologous and allogeneic B lymphoid cell lines (B-LCL) was evaluated 24, 48 and 96 h after stimulation. ConA-stimulated CD4+ cells from MS patients did not produce significantly more IL-2 than normal CD4+ cells. In contrast, autologous B-LCL-induced IL-2 production by MS CD4+ cells significantly (P = 0.026) exceeded that produced by normal CD4+ cells identically stimulated after 24 h in culture. Differences in IL-2 production by CD4+ cells from MS patients reached highest significance using allogeneic B-LCL, whose stimulatory capacity was similar, whether established from normal individuals or MS patients. This increased IL-2 production in response to B-LCL may represent a supranormal response of CD4+ cells from MS patients to class II major histocompatibility (MHC)-associated stimuli. It suggests that the deficiency of suppressor T cell functions postulated to play a role in MS does not arise from a lack of IL-2 induction and might indicate that bursts of IL-2 production could play a role in MS.lld:pubmed
pubmed-article:3492511pubmed:languageenglld:pubmed
pubmed-article:3492511pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3492511pubmed:citationSubsetIMlld:pubmed
pubmed-article:3492511pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3492511pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3492511pubmed:statusMEDLINElld:pubmed
pubmed-article:3492511pubmed:monthFeblld:pubmed
pubmed-article:3492511pubmed:issn0165-5728lld:pubmed
pubmed-article:3492511pubmed:authorpubmed-author:GoustJ MJMlld:pubmed
pubmed-article:3492511pubmed:authorpubmed-author:VerselisS JSJlld:pubmed
pubmed-article:3492511pubmed:issnTypePrintlld:pubmed
pubmed-article:3492511pubmed:volume14lld:pubmed
pubmed-article:3492511pubmed:ownerNLMlld:pubmed
pubmed-article:3492511pubmed:authorsCompleteYlld:pubmed
pubmed-article:3492511pubmed:pagination75-85lld:pubmed
pubmed-article:3492511pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3492511pubmed:meshHeadingpubmed-meshheading:3492511-...lld:pubmed
pubmed-article:3492511pubmed:meshHeadingpubmed-meshheading:3492511-...lld:pubmed
pubmed-article:3492511pubmed:meshHeadingpubmed-meshheading:3492511-...lld:pubmed
pubmed-article:3492511pubmed:meshHeadingpubmed-meshheading:3492511-...lld:pubmed
pubmed-article:3492511pubmed:meshHeadingpubmed-meshheading:3492511-...lld:pubmed
pubmed-article:3492511pubmed:meshHeadingpubmed-meshheading:3492511-...lld:pubmed
pubmed-article:3492511pubmed:meshHeadingpubmed-meshheading:3492511-...lld:pubmed
pubmed-article:3492511pubmed:meshHeadingpubmed-meshheading:3492511-...lld:pubmed
pubmed-article:3492511pubmed:meshHeadingpubmed-meshheading:3492511-...lld:pubmed
pubmed-article:3492511pubmed:year1987lld:pubmed
pubmed-article:3492511pubmed:articleTitleCD4+ T cell activation in multiple sclerosis.lld:pubmed
pubmed-article:3492511pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3492511pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed